Form 4: Ligand Pharmaceuticals Executive Sells Shares
Insider Transaction (Form 4)
Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals Inc, sold 5,000 shares of common stock on October 2, 2026.
Summary
- Option exercise/conversion: acquired 340 Common Stock at $52.27 ($17,772) on October 2, 2026; holds 36,854 after (Direct).
- Open-market sale: disposed of 833 Common Stock at $302.51 ($251,991) on October 2, 2026; holds 36,021 after (Direct).
- Open-market sale: disposed of 1,976 Common Stock at $303.54 ($599,804) on October 2, 2026; holds 34,045 after (Direct).
- Open-market sale: disposed of 1,535 Common Stock at $304.52 ($467,431) on October 2, 2026; holds 32,510 after (Direct).
- Open-market sale: disposed of 404 Common Stock at $306.18 ($123,698) on October 2, 2026; holds 32,106 after (Direct).
- Open-market sale: disposed of 235 Common Stock at $307.19 ($72,190) on October 2, 2026; holds 31,871 after (Direct).
- Open-market sale: disposed of 17 Common Stock at $307.74 ($5,232) on October 2, 2026; holds 31,854 after (Direct).
- Option exercise/conversion: disposed of 340 Employee Stock Option (right to buy) on October 2, 2026; holds 29,104 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,520,346 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Andrew Reardon — Officer (CLO & Secretary)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-02 | Option exercise/conversion | Common Stock | 340 | $52 | $17.8K | 36,854 |
| 2026-10-02 | Open-market sale | Common Stock | 833 | $303 | $252.0K | 36,021 |
| 2026-10-02 | Open-market sale | Common Stock | 1,976 | $304 | $599.8K | 34,045 |
| 2026-10-02 | Open-market sale | Common Stock | 1,535 | $305 | $467.4K | 32,510 |
| 2026-10-02 | Open-market sale | Common Stock | 404 | $306 | $123.7K | 32,106 |
| 2026-10-02 | Open-market sale | Common Stock | 235 | $307 | $72.2K | 31,871 |
| 2026-10-02 | Open-market sale | Common Stock | 17 | $308 | $5.2K | 31,854 |
| 2026-10-02 | Option exercise/conversion | Employee Stock Option (right to buy) | 340 | — | — | 29,104 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-02 | Option exercise/conversion (340 shares) |
| 2026-10-02 | Open-market sale (833 shares) |
| 2026-10-02 | Open-market sale (1,976 shares) |
| 2026-10-02 | Open-market sale (1,535 shares) |
| 2026-10-02 | Open-market sale (404 shares) |
| 2026-10-02 | Open-market sale (235 shares) |
| 2026-10-02 | Open-market sale (17 shares) |
| 2026-10-02 | Option exercise/conversion (340 shares) |
Keywords
insider transaction, Form 4, LGND, LIGAND PHARMACEUTICALS INC, bearish, Andrew Reardon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.